Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

4.95
+0.05001.02%
Post-market: 4.950.00000.00%19:30 EDT
Volume:240.38K
Turnover:1.18M
Market Cap:296.41M
PE:-4.95
High:5.01
Open:4.92
Low:4.83
Close:4.90
52wk High:5.78
52wk Low:2.20
Shares:59.88M
Float Shares:33.00M
Volume Ratio:0.96
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:15.34
PE(LYR):-4.46

Loading ...

Orchestra granted additional breakthrough device designation for AVIM therapy

TIPRANKS
·
May 01

Orchestra BioMed wins FDA Breakthrough Device designation for AVIM hypertension therapy

Reuters
·
Apr 30

FDA Grants Orchestra Biomed Additional Breakthrough Device Designation for Avim Therapy

THOMSON REUTERS
·
Apr 30

RTW Investments reports disposal of 32 Orchestra BioMed shares for $132.16

Reuters
·
Apr 30

Orchestra BioMed says MODERATO II trial shows 13.2 mmHg AVIM blood pressure drop

Reuters
·
Apr 24

Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters
·
Apr 06

Orchestra BioMed publishes corporate deck highlighting pivotal AVIM hypertension, Virtue SAB artery disease trials

Reuters
·
Mar 30

Orchestra BioMed Publishes CRT 2026 AVIM Therapy Presentation

Reuters
·
Mar 24

Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH)

TIPRANKS
·
Mar 18

Orchestra BioMed CEO and Chairperson David P. Hochman acquires USD 42,900 in common shares

Reuters
·
Mar 17

Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate

Benzinga Earnings
·
Mar 12

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire
·
Mar 12

Orchestra BioMed FY2025 net loss narrows 14% to USD 52.7 million

Reuters
·
Mar 12

Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle

TIPRANKS
·
Mar 12

Orchestra BioMed management to meet with B. Riley

TIPRANKS
·
Mar 09